National Institute of Mental Health

The National Institute of Mental Health (NIMH) is the lead federal agency for research on mental disorders, operating under the U.S. National Institutes of Health (NIH). NIMH funds a significant share of psychedelic clinical research in the United States, particularly trials investigating psilocybin and ketamine for depression and anxiety disorders.

National Institute of Mental Health

Quick Facts

Sponsored Trials

Understanding and Treating Suicidal Ideation With Ketamine

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Behavioural Activation Therapy and Esketamine for Resistant Depression

[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine

Long-term Observation of Participants With Mood Disorders

Psilocybin Versus Ketamine in Treatment-Resistant Depression (PSIKET_001)

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

Mechanism of Action Underlying Ketamine’s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

Rapid Antidepressant Effects of Ketamine in Major Depression

Collaborated Trials

Psilocybin Therapy for Psychological Distress in Palliative Patients (PsyPal)

Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PREPARE-2)

Cognitive Training as an Adjunct to Ketamine in Real-world Clinics

Examining Mu Opioid Mechanisms of Ketamine’s Rapid Effects in OCD (MKET2) (MKET2)

Neural Circuit Effects of Ketamine in Depression

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

Ketamine Treatment of Youth Suicide Attempters

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Ketamine in the Treatment of Suicidal Depression

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention (ENDURE)

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

IM Ketamine vs Midazolam for Suicidal ER Patients

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study

Physiological and Cognitive Biomarkers for Ketamine’s Antidepressant Effects

miRNAs, Suicide, and Ketamine – Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Biomarkers of Fast Acting Therapies in Major Depression

Company

Product

Legal